Please use this identifier to cite or link to this item:
|Title:||Urothelial cancers: using biology to improve outcomes.|
|Authors:||Pezaro, Carmel;Liew, Mun Sem;Davis, Ian D|
|Affiliation:||Joint Ludwig Austin Oncology Unit, Austin Hospital LTB6, Heidelberg, VIC 3084, Australia.|
|Citation:||Expert Review of Anticancer Therapy; 12(1): 87-98|
|Abstract:||Urothelial carcinoma (transitional cell carcinoma) is the most common malignancy of the urinary tract. Urothelial carcinoma of the bladder is a common disease but has traditionally been underrepresented in both public awareness and cancer research. The purpose of this review is to provide an outline of the recent updates in understanding of urothelial cancer etiology, particularly with regards to lower tract muscle-invasive disease, and to discuss the identified mutations in high- and low-grade disease. We will consider evidence for the current systemic therapies for muscle-invasive and metastatic disease and review the targeted therapies under investigation for advanced urothelial cancer.|
|Internal ID Number:||22149435|
|Subjects:||Carcinoma, Transitional Cell.drug therapy.pathology|
Clinical Trials as Topic
Randomized Controlled Trials as Topic
Urinary Bladder Neoplasms.drug therapy.pathology
|Appears in Collections:||Journal articles|
Files in This Item:
There are no files associated with this item.
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.